Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
Kodiak's stock doubles with win for resurrected eye disease drug
Two of Kodiak's candidates matched aflibercept in a phase 3 trial, positioning the biotech to seek approval of one of the eye disease assets this year.
Nick Paul Taylor
Sep 28, 2026 8:37am
J&J axes eye disease gene therapy after key phase 2b readout
Jul 15, 2026 10:26am
Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet
Jun 24, 2026 7:00am
Discreet biotech Osanni Bio starts making noise with $190M
Jun 23, 2026 2:28pm
Ocugen eye disease gene therapy nabs ph. 2 win
Mar 24, 2026 10:40am
Innovent eyes China approval after matching Eylea in phase 3
Mar 24, 2026 6:00am
